Journal
MOLECULAR PHARMACOLOGY
Volume 68, Issue 2, Pages 330-335Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.104.008722
Keywords
-
Categories
Funding
- NCI NIH HHS [CA87584] Funding Source: Medline
- NHLBI NIH HHS [HL072925] Funding Source: Medline
- NIGMS NIH HHS [GM08716, GM62887] Funding Source: Medline
Ask authors/readers for more resources
The ability of pro-inflammatory cytokines such as interleukin-1 beta (IL-1 beta) to induce the major inflammatory mediator prostaglandin (PG) E-2 depends on the activation of two rate-limiting enzymes, phospholipase A(2) (PLA(2)) and cyclooxygenase 2 (COX-2). PLA(2) acts to generate arachidonic acid, which serves as the precursor substrate for COX-2 in the metabolic pathway leading to PGE(2) production. However, less is known about the mechanisms that coordinate the regulation of these two enzymes. We have provided prior evidence that sphingosine kinase 1 and its bioactive lipid product sphingosine-1-phosphate (S1P) mediate the effects of cytokines on COX-2 induction, whereas ceramide kinase and its distinct product, ceramide-1-phosphate (C1P), are required for the activation and translocation of cPLA(2) (FASEB J 17: 1411 - 1421. 2003; J Biol Chem 278: 38206 - 38213, 2003; J Biol Chem 279: 11320 - 11326, 2004). Herein, we show that these two pathways are independent but coordinated, resulting in synergistic induction of PGE(2). Moreover, the combination of both S1P and C1P recapitulates the temporal and spatial activation of cPLA(2) and COX-2 seen with IL-1 beta. Taken together, the results provide, for the first time, a mechanism that assures the coordinate expression and activation in time and space of COX-2 and cPLA(2), assuring maximal production of PGE(2).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available